Department of Neurology, Mayo Clinic Rochester, 200 1st St SW, Rochester, MN, 55905, USA.
Department of Medical Oncology, Mayo Clinic Rochester, 200 1st St SW, Rochester, MN, 55905, USA.
Curr Treat Options Oncol. 2019 Mar 14;20(4):25. doi: 10.1007/s11864-019-0625-6.
In the context of the new WHO classification system, all low-grade gliomas must have an IDH mutation, with or without 1p/19q codeletion. Upon discovery of the tumor, maximal safe surgical resection is the most appropriate first step due to the current inability to differentiate between IDH mutant and IDH wild-type tumors by imaging alone. In the postoperative setting, based on the synthesis and interpretation of the available data, we recommend utilizing conventional radiation therapy and PCV in all high-risk-low-grade gliomas. For patients felt to be in a low risk category, we recommend maintaining a low threshold to initiate treatment. In the setting of tumor recurrence, consideration of all treatment options is reasonable, but treatment with alkylator therapy has the strongest supporting data.
在新的世界卫生组织分类系统中,所有低级别胶质瘤必须有 IDH 突变,无论是否有 1p/19q 联合缺失。发现肿瘤后,由于目前仅凭影像学无法区分 IDH 突变型和 IDH 野生型肿瘤,最大限度的安全手术切除是最合适的第一步。在术后,根据现有数据的综合和解释,我们建议在所有高危低级别胶质瘤中使用常规放疗和 PCV。对于被认为处于低危类别的患者,我们建议保持较低的治疗门槛。在肿瘤复发的情况下,考虑所有的治疗方案都是合理的,但烷化剂治疗的数据支持最强。